FDA Demands Additional Safety Data From Eli Lilly's Foundayo

In approval documents released April 14, the FDA requested further data on Foundayo (orforglipron), an oral GLP-1, concerning links to myocardial infarction, stroke, and drug-induced liver injury. The second GLP-1 pill to launch raises both price competition and safety scrutiny as access widens.